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Abstract
Background Limited prospective data are available on the
long-term safety of darbepoetin alfa (DA) for treating anemia
in children with chronic kidney disease (CKD).
Methods In this prospective, phase IV, observational registry
study, children ≤16 years of age with CKD anemia and receiv-
ing DA were observed for ≤2 years. Adverse events (AEs),
DA dosing, hemoglobin (Hb) concentrations, and transfusions
were recorded.
Results A total of 319 patients were included in the analysis
(mean age, 9.1 years), 158 (49.5 %) of whom were on dialysis
at study entry. Of 434 serious AEs reported in 162 children,
the most common were peritonitis (10.0 %), gastroenteritis
(6.0 %), and hypertension (4.1 %). Six patients (1.9 %) died
(unrelated to DA). Four patients (1.3 %) experienced six seri-
ous adverse drug reactions. The geometric mean DA dose
range was 1.4–2.0 μg/kg/month. Mean baseline Hb concen-
tration was 11.1 g/dl; mean values for children receiving and
not receiving dialysis at baseline ranged between 10.9 and
11.5 g/dl and 11.2–11.7 g/dl, respectively. Overall, 48 patients
(15.0 %) received ≥1 transfusion.
Conclusions No new safety signals for DAwere identified in
children receiving DA for CKD anemia for ≤2 years. Based on
Hb concentrations and transfusion requirements, DA was ef-
fective at managing anemia in these patients.
Keywords Adverse events . Anemia . Chronic kidney
disease . Darbepoetin alfa . Hemoglobin . Pediatric
Introduction
Although the prevalence of chronic kidney disease (CKD) in
children is much lower than in adults, the condition is associ-
ated with substantial mortality and morbidity in the pediatric
population. Despite evidence of improved long-term survival
rates, mortality in children and adolescents is 55 times greater
in those on renal replacement therapy than in children without
end-stage renal disease [1, 2]. Hypertension and anemia are
common complications [3–7]. In a large cohort of North
American children aged ≥2 years with CKD and not on dial-
ysis, anemia prevalence increased from 18.5 % in those at
stage II to 68% of those at stage V, and the presence of anemia
significantly increased the risk of hospitalization [8].
Anemia in children with CKD can be corrected with iron
supplements and erythropoiesis-stimulating agents (ESAs),
although some evidence suggests these treatments may be
under-utilized. In CKD patients receiving dialysis, for exam-
ple, relatively fewer children than adults achieve target hemo-
globin (Hb) [9], and in 1,724 children and adolescents in the
North American Pediatric Renal Transplant Cooperative
Study database, of whom 31 % had anemia (hematocrit
<30 %), only 13 % were receiving erythropoietin [4].
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Currently, darbepoetin alfa (DA) is indicated for the treat-
ment of anemia in adults and children with CKD, whether or
not they are receiving dialysis [10]. DA is administered either
subcutaneously (s.c.) or intravenously (i.v.) with the aim of
increasing Hb to a value between 10 and 12 g/dl, or between
9.5 and 11.5 g/dl if<2 years of age [11]. Dosing recommen-
dations for children aged ≥11 years are very similar to those
for adults, but recommendations for children aged <11 years
are not yet available. In an open-label study of children aged
1–18 years with an estimated glomerular filtration rate (eGFR)
of <30 ml/min × 1.73 m2, DAwas found to be non-inferior to
recombinant human erythropoietin (rHuEpo) for treating ane-
mia [12], but the follow-up in this and other studies that eval-
uated the use of DA in children aged <11 years [13–16] was
limited to 28 weeks.
Here, we present the final results of a prospective observa-
tional registry study that aimed to evaluate the safety of DA in
anemic children with CKD over a longer period (2 years), and
to investigate dosage patterns and Hb concentrations over
time.
Methods
Study design and patient selection
This prospective phase IV observational registry study
(NCT00838097) enrolled patients from 37 pediatric nephrol-
ogy centers in 13 European countries from February 2008 to
February 2011. The centers all had experience in treating pe-
diatric CKD patients with DA in routine clinical practice.
To be eligible for inclusion, children and adolescents aged
0–16 years with anemia attributed to CKD had to either be
receiving dialysis or have an eGFR of <60 ml/min × 1.73 m2
for at least 3 months, and be receiving DA at the time of study
enrollment. Patients were excluded if they had active malig-
nancy or were receiving chemotherapy or radiotherapy.
Patients were followed up for a maximum of 2 years, or
until the time of study withdrawal if this occurred earlier.
Protocol-specified reasons for premature study withdrawal in-
cluded permanent cessation of DA treatment, renal transplan-
tation, enrollment into an interventional study, or withdrawal
of informed consent. Reasons for withdrawal and for stopping
DA treatment were recorded.
In accordance with the observational design, the DA treat-
ment regimen was not pre-specified and treating physicians
could alter treatment dosage or temporarily suspend treatment
at any time.
Data collection
Baseline data collected for each patient, if available,
included demographic and clinical characteristics,
medical history (including history and cause of CKD
and time of diagnosis, transplant and dialysis history,
co-morbidities, red blood cell [RBC] transfusions in
the previous year and history of ESA use), dosing in-
formation for DA (date of first use, dose, frequency,
and administration route), and Hb concentration levels
at entry and during the 3 previous months. At 3-
monthly intervals thereafter, the key parameters recorded
were DA dosing information, Hb concentrations, infor-
mation on dialysis if started since the previous assess-
ment, renal transplants and RBC transfusions received,
details of iron supplementation, and hospitalizations. All
data available from each patient’s medical record were
abstracted to electronic case report forms (eCRFs).
All adverse events (AEs) were recorded in the eCRF from
the time of informed consent to the end of the study period.
The three co-primary endpoints were the incidences of serious
AEs (SAEs), serious adverse drug reactions (SADRs; i.e.,
SAEs considered by the treating physician to be associated
with exposure to DA), and the following protocol-specified
events of medical interest (EMIs): thromboembolic events,
seizures, severe hypertension, cardiovascular events (e.g., ar-
rhythmia and heart failure), pure red cell aplasia, and hyper-
sensitivity reactions. For severe hypertension, no threshold
blood pressure (BP) value was pre-defined; these events were
reported at the discretion of the treating physician. The rela-
tionship of any AE to DA treatment was also assessed by the
treating physician. Secondary endpoints were the incidence of
non-SADRs, and the DA dose and Hb concentrations over
time.
Statistical analyses
No formal hypotheses were tested. Patient disposition, de-
mographic and clinical characteristics, medical history, and
previous ESA therapy were summarized descriptively. For
the analysis of SAEs, SADRs, and EMIs, exposure-
adjusted incidence rates and incidence rates based on
life-table methodology were summarized together with
95 % confidence intervals (CIs), and the number of pa-
tients affected were summarized by preferred term and
system organ class. The population used for all analyses
was the full analysis set (FAS), i.e., all patients who re-
ceived at least one dose of DA. Analyses were also done
for four age subgroups (<1 year, 1–5 years, 6–11 years,
and ≥12 years) and two dialysis subgroups (on dialysis at
baseline or not). Non-SADRs were summarized by pre-
ferred term and system organ class.
The actual and weight-adjusted doses of DA were sum-
marized monthly using descriptive statistics, as well as the
cumulative DA dose over the duration of the study.
Changes in DA dose (actual and weight-adjusted) from
baseline were also summarized descriptively. Hb
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concentration was summarized at baseline and at 3-
monthly periods. RBC transfusions were summarized by
tabulating the incidence of transfusions as well as the
number of transfusions received per patient over the study
duration. Information on body weight, BP, and other lab-
oratory test data were also collected (data not shown).
Results
Patients and treatment
Of the 321 patients who entered the study, 145 (45.2 %)
patients completed the study, and 176 (54.8 %) with-
drew early, most commonly because of renal transplan-
tation (121 [37.7 %] patients). Twenty patients (6.2 %)
stopped DA treatment permanently, 11 (3.4 %) were lost
to follow-up, and six patients (1.9 %) died. The reasons
for study withdrawal in the other 16 patients are shown
in Fig. 1. Two of the 321 patients who entered did not
receive DA; the remaining 319 were included in the
FAS. The median duration of follow-up (from first dose
to the end of the study) was 88 weeks (range, 1–117
weeks); the median duration of treatment (from the first
to the last dose of DA) was the same. A marked dif-
ference was seen in follow-up duration between those
on dialysis at baseline and those who were not (medians
of 57 and 102 weeks, respectively).
The mean age of patients in the FAS was 9.1 (standard
deviation [SD], 5.0) years: the largest age subgroup was chil-
dren aged ≥12 years (n=133) and the smallest was infants aged
<1 year (n=13) (Table 1). The majority of patients were male
(55.5 %). Of the specified primary causes of CKD, the most
common were glomerulopathies (24.8 %), renal hypoplasia/
dysplasia (23.2 %), obstructive nephropathy (11.6 %), and
polycystic kidney disease (7.8 %) (Table 1). The distribution
of etiologies varied very little by age subgroup.
Hypertension was the most common co-morbidity in the
FAS, experienced currently or previously by 155 (48.6 %)
patients, 137 of whom were receiving antihypertensive treat-
ment at baseline. Other co-morbidities were less common,
mostly affecting <10 % of patients (except for neurological
conditions: 55 [17.2 %] patients).
At baseline, the mean Hb concentration for all patients with
available data (n=308) was 11.1 (SD, 1.6) g/dl: the mean value
was lower in children aged <1 year (10.6 g/dl) than in the other
three age subgroups (11.0–11.2 g/dl). Baseline Hb values were
within the 10–12 g/dl range in 161 (50.5 %) of the patients; the
number of patients with baseline Hb values above 12 g/dl (77;
24.1 %) or below 10 g/dl (70; 21.9 %) were similar. Of 319
patients in the FAS, 158 (49.5 %) were on dialysis at study
entry. The proportions on hemodialysis and peritoneal dialysis
in the FAS were similar (74 [23.2 %] and 84 [26.3 %], respec-
tively), but varied by age subgroup, with older children gener-
ally more likely to be on hemodialysis than younger children
(Table 1). In 158 patients with available data, the median du-
ration of dialysis before study entry was 9.7 months (range, 0–
190 months). Sixty-six (20.7 %) patients had previously re-
ceived a kidney transplant. The mean (SD) eGFR at baseline
in the 142 non-dialysis patients was 37 (23) ml/min × 1.73 m2.
During the 12 months before study entry, 267 patients
(83.7 %) had been treated with DA, 98 (30.7 %) had received
epoetin-beta, 13 (4.1 %) had received epoetin-alfa, and 16







Adverse event, 2 (0.6%)
Consent withdrawn, 3 (0.9%)
Required alternative therapy, 2 (0.6%)
Administrative reasons, 4 (1.2%)
Lost to follow-up, 11 (3.4%)
Death, 6 (1.9%)
Protocol-specified criteria:
Renal transplant, 121 (37.7%)
Permanently discontinued DA, 20 (6.2%)









Fig. 1 Patient disposition.
Reasons for premature
withdrawal are shown as % of all
patients enrolled. DA darbepoetin
alfa
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(93.7 %) were being treated with DA, with a geometric mean
dose of 52.6 μg/month, and a weight-adjusted value of
1.99 μg/kg/month (95 % CI: 1.82–2.18; n=273). The
weight-adjusted geometric mean doses at baseline for i.v.
and s.c. routes, respectively, were 2.89 μg/kg/month (95 %
CI: 2.43–3.43) and 1.75 μg/kg/month (95 % CI: 1.58–1.93).
The 20 patients who were not receiving DA at enrollment
started treatment 2–84 days (median, 9 days) after enrollment;
although classed as protocol violators, they were included in
all analyses.
Tolerability and safety
Serious adverse events and deaths A total of 162 (50.8 %)
patients reported a total of 434 SAEs, equating to an exposure-
adjusted event rate (EAER) of 101.8 per 100 person-years











Male patients, n (%) 177 (55.5) 8 (61.5) 49 (59.0) 49 (54.4) 71 (53.4)
Age at diagnosis of CKD, years
(mean and SD; n=317)
3.6 (4.5) 0.1 (0.2) 1.0 (1.4) 3.5 (3.4) 5.8 (5.4)
Race, n (%)
White/Caucasian 274 (85.9) 13 (100) 75 (90.4) 77 (85.6) 109 (82.0)
Black/African American 9 (2.8) 0 0 3 (3.3) 6 (4.5)
Asian 8 (2.5) 0 3 (3.6) 4 (4.4) 1 (0.8)
Other 9 (2.8) 0 3 (3.6) 2 (2.2) 4 (3.0)
Not recorded 19 (6.0) 0 2 (2.4) 4 (4.4) 13 (9.8)
Primary etiology of CKD, n (%)
Glomerulopathies 79 (24.8) 1 (7.7) 20 (24.1) 22 (24.4) 36 (27.1)
Renal dysplasia/hypoplasia 74 (23.2) 2 (15.4) 23 (27.7) 24 (26.7) 25 (18.8)
Obstructive nephropathy 37 (11.6) 3 (23.1) 10 (12.0) 5 (5.6) 19 (14.3)
Polycystic kidney disease 25 (7.8) 2 (15.4) 12 (14.5) 7 (7.8) 4 (3.0)
Reflux nephropathy 20 (6.3) 2 (15.4) 2 (2.4) 7 (7.8) 9 (6.8)
Nephronophthisis 18 (5.6) 1 (7.7) 1 (1.2) 2 (2.2) 14 (10.5)
Hemolytic uremic syndrome 17 (5.3) 0 3 (3.6) 10 (11.1) 4 (3.0)
Post-ischemic nephropathy 11 (3.5) 1 (7.7) 5 (6.0) 4 (4.4) 1 (0.8)
Other specified causes 24 (7.5) 1 (7.7) 5 (6.0) 6 (6.7) 12 (9.0)
Unknown or not recorded 14 (4.4) 0 2 (2.4) 3 (3.3) 9 (6.8)
Baseline hemoglobin concentration, n (%)
<10 g/dl 70 (21.9) 3 (23.1) 18 (21.7) 20 (22.2) 29 (21.8)
10–12 g/dl 161 (50.5) 6 (46.2) 41 (49.4) 50 (55.6) 64 (48.1)
>12 g/dl 77 (24.1) 3 (23.1) 21 (25.3) 18 (20.0) 35 (26.3)
Missing 11 (3.4) 1 (7.7) 3 (3.6) 2 (2.2) 5 (3.8)
ESA use at study entry, n (%)
Intravenous DA 80 (25.1) 2 (15.4) 11 (13.3) 20 (22.2) 47 (35.3)
Subcutaneous DA 219 (68.7) 10 (76.9) 63 (75.9) 64 (71.1) 82 (61.7)
Not on DAa 20 (6.2) 1 (7.7) 9 (10.8) 6 (6.7) 4 (3.0)
Previous kidney transplants, n (%)
≥1 RBC transfusion in previous year, n (%) 66 (20.7) 0 7 (8.4) 19 (21.1) 40 (30.1)
Dialysis status at baseline 57 (17.9) 3 (23.1) 19 (22.9) 15 (16.7) 20 (15.0)
Conservative treatment (no dialysis) 160 (50.2) 6 (46.2) 42 (50.6) 48 (53.3) 64 (48.1)
Hemodialysis 74 (23.2) 1 (7.7) 11 (13.3) 18 (20.0) 44 (33.1)
Peritoneal dialysis 84 (26.3) 6 (46.2) 30 (36.1) 24 (26.7) 24 (18.0)
Unknown 1 (0.3) 0 0 0 1 (0.8)
CKD chronic kidney disease; DA darbepoetin alfa; ESA erythropoiesis stimulating agent; RBC red blood cells; SD standard deviation
a Protocol violation
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[95 % CI: 92.5–111.9]. The three most common SAEs were
peritonitis (32 patients; 10.0 % of FAS), gastroenteritis (19
patients; 6.0 %), and hypertension (13 patients; 4.1 %). All
SAEs of peritonitis (44 events) were reported by patients who
were on dialysis (mostly peritoneal) at the time of the event.
Details are shown in Tables 2, 3, and 4.
Six patients (1.9 %) had fatal AEs during the study. The
fatal AEs in the younger children were gastrointestinal necro-
sis, pulmonary edema, and severe hypertension leading to
cardiac arrest (in patients aged 15, 11, and 6 months, respec-
tively), and in the three older children, the causes of death
were congenital mitochondrial cytopathy, pulmonary edema,
and sepsis (in patients aged 5, 15, and 7 years old, respective-
ly). No fatal AE was considered to be related to DA
administration.
Adverse drug reactions Four patients (1.3 %) experi-
enced six SADRs: arteriovenous fistula thrombosis and
embolism (single episode), priapism, thrombocytopenia,
hemolysis, hemolytic anemia, and partial blindness. Two
patients were in the 6–11 years age group, and two in
the ≥12 years group (Table 5). Injection site pain was
reported as a non-SADR by four patients (1.3 %), aged
1, 6, 10, and 12 years old.
Events of medical interest A total of 39 patients (12.2 %)
reported a total of 82 EMIs in four categories: severe hyper-
tension (34 events in 21 patients), seizures (24 in 14 patients),
thromboembolic/cardiovascular events (21 in 12 patients), and
hypersensitivity reactions (three in three patients). The EAER
per 100 person-years for all EMIs was 19.2 [95 % CI: 15.3–
23.9]. The three most commonly reported EMIs were hyper-
tension (15 patients; 4.7 %), convulsions (ten patients; 3.1 %),
and hypertensive crisis (five patients; 1.6 %). The EAERs for
these three events were 5.9 (95 % CI: 3.8–8.7), 3.8 (2.2–6.1),
and 1.4 (0.5–3.1), respectively. One patient had simultaneous
convulsions and hypertensive crisis. All other EMIs were re-
ported by either one or two patients (EAERs, 0.2 [0.0–1.3]
and 0.5 [0.1–1.7]). The proportion of children reporting EMIs
was higher in the three younger age subgroups (14–15 %) than
the oldest group (9 %).
Table 2 Most common serious
adverse events in the full





Events, n EAER/100 person-years
(95 % CI)
Any SAE 162 (50.8) 434 101.8 (92.5–111.9)
Peritonitis 32 (10.0) 44 10.3 (7.5–13.9)
Hypertension 13 (4.1) 23 5.4 (3.4–8.1)
Gastroenteritis 19 (6.0) 22 5.2 (3.2–7.8)
Convulsions 10 (3.1) 16 3.8 (2.2–6.1)
Diarrhea 8 (2.5) 11 2.6 (1.3–4.6)
Vomiting 8 (2.5) 8 1.9 (0.8–3.7)
Urinary tract infection 7 (2.2) 8 1.9 (0.8–3.7)
Renal failure chronic 7 (2.2) 7 1.6 (0.7–3.4)
Sepsis 7 (2.2) 7 1.6 (0.7–3.4)
Pneumonia 6 (1.9) 7 1.6 (0.7–3.4)
Pyelonephritis 6 (1.9) 7 1.6 (0.7–3.4)
Pyrexia 4 (1.3) 7 1.6 (0.7–3.4)
Medical device complication 4 (1.3) 6 1.4 (0.5–3.1)
Bronchitis 6 (1.9) 6 1.4 (0.5–3.1)
Catheter site infection 6 (1.9) 6 1.4 (0.5–3.1)
Device-related infection 6 (1.9) 6 1.4 (0.5–3.1)
Dehydration 6 (1.9) 6 1.4 (0.5–3.1)
Hypertensive crisis 5 (1.6) 6 1.4 (0.5–3.1)
Abdominal pain 3 (0.9) 5 1.2 (0.4–2.7)
Upper respiratory tract infection 4 (1.3) 5 1.2 (0.4–2.7)
Arteriovenous fistula thrombosis 5 (1.6) 5 1.2 (0.4–2.7)
Hyperkalemia 3 (0.9) 5 1.2 (0.4–2.7)
CI confidence interval; EAER exposure-adjusted event rate; SAE serious adverse event
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Darbepoetin alfa dose
The overall geometric mean monthly weight-adjusted DA
dose was relatively stable over time, ranging from 1.6 to
2.0 μg/kg from baseline to month 12 (n=211–273) and from
1.4 to 1.8 μg/kg in the second 12 months (n=146–206). The
mean i.v. dose range was higher than the s.c. dose range,
particularly in the first 9 months (Fig. 2a). Over the full
study period, children on dialysis at baseline received higher
geometric mean DA doses than those who were not (1.9–
2.7 μg/kg and 1.3–1.6 μg/kg, respectively) and were more
likely to receive i.v. dosing than those not on dialysis: 58/
124 (46.7 %) and 16/145 (11.0 %), respectively, at month 6
and 37/90 (41.1 %) and 15/121 (12.4 %), respectively, at
month 12.
Over the course of the study, the younger children received
higher geometric mean weight-adjusted DA doses (1.7–
3.2μg/kg/month for those aged <1 year; 1.9–2.7μg/kg/month
for those aged 1–5 years) than the older children (1.5–2.0 and
1.2–1.8 μg/kg/month for those aged 6–11 and ≥12 years,
respectively), although 95% CIs for the children aged <1 year
(n=13) were very wide (Fig. 2b).
Throughout the study, the weight-adjusted geometric mean
monthly dose was higher in patients receiving dialysis than in
patients not on dialysis (Fig. 2c). In patients who were not on
dialysis at each time point, the geometric mean DA dose
followed a downward trend throughout the study. In patients
on peritoneal dialysis at each time point, the geometric mean
monthly DA dose was generally higher in the second year of
the study than the first, but in hemodialysis patients, values
were generally lower in the later part of the study than in the
first 6 months.
Hemoglobin concentrations
In months 1–3, the mean Hb concentration for all patients rose
to 11.5 g/dl (from a baseline value of 11.1 g/dl), with little
change during the remainder of the study (range from months
4–24=11.3–11.4 g/dl).Mean values for each age subgroup are
shown in Fig. 2d. The spread of mean Hb concentrations
Table 4 Most common serious adverse events in the full analysis set (those with exposure-adjusted event rates per 100 person-years of >1) broken
down for subgroups receiving and not receiving dialysis at baseline (data for one patient with unknown dialysis status at baseline not shown)









Any SAE 77 (48.1) 73.8 (63.5–85.3) 85 (53.8) 140.3 (123.5–158.8)
Peritonitis 7 (4.4) 3.2 (1.4–6.4) 25 (15.8) 20.1 (14.0–27.8)
Hypertension 2 (1.3) 1.6 (0.4–4.2) 11 (7.0) 10.6 (6.4–16.5)
Gastroenteritis 11 (6.9) 5.7 (3.1–9.5) 8 (5.1) 4.5 (1.9–8.8)
Convulsions 4 (2.5) 1.6 (0.4–4.2) 6 (3.8) 6.7 (3.5–11.7)
Diarrhea 3 (1.9) 2.0 (0.7–4.7) 5 (3.2) 3.3 (1.2–7.3)
Vomiting 1 (0.6) 0.4 (0.0–2.3) 7 (4.4) 3.9 (1.6–8.0)
Urinary tract infection 6 (3.8) 2.8 (1.1–5.9) 1 (0.6) 0.6 (0.0–3.1)
Renal failure chronic 6 (3.8) 2.4 (0.9–5.3) 1 (0.6) 0.6 (0.0–3.1)
Sepsis 4 (2.5) 1.6 (0.4–4.2) 3 (1.9) 1.7 (0.3–4.9)
Pneumonia 4 (2.5) 1.6 (0.4–4.2) 2 (1.3) 1.7 (0.3–4.9)
Pyelonephritis 4 (2.5) 1.6 (0.4–4.2) 2 (1.3) 1.7 (0.3–4.9)
Pyrexia 1 (0.6) 0.4 (0.0–2.3) 3 (1.9) 3.3 (1.2–7.3)
Medical device complication 0 0 4 (2.5) 3.3 (1.2–7.3)
Bronchitis 4 (2.5) 1.6 (0.4–4.2) 2 (1.3) 1.1 (0.1–4.0)
Catheter site infection 0 0 6 (3.8) 3.3 (1.2–7.3)
Device-related infection 0 0 6 (3.8) 3.3 (1.2–7.3)
Dehydration 4 (2.5) 1.6 (0.4–4.2) 2 (1.3) 1.1 (0.1–4.0)
Hypertensive crisis 2 (1.3) 0.8 (0.1–2.9) 3 (1.9) 2.2 (0.6–5.7)
Abdominal pain 2 (1.3) 0.8 (0.1–2.9) 1 (0.6) 1.7 (0.3–4.9)
Upper respiratory tract infection 0 0 4 (2.5) 2.8 (0.9–6.5)
Arteriovenous fistula thrombosis 1 (0.6) 0.4 (0.0–2.3) 4 (2.5) 2.2 (0.6–5.7)
Hyperkalemia 1 (0.6) 0.8 (0.1–2.9) 2 (1.3) 1.7 (0.3–4.9)
CI confidence interval; EAER exposure-adjusted event rate; SAE serious adverse event
Pediatr Nephrol (2016) 31:443–453 449
during the study period was similar for patients who were on
dialysis at baseline (10.9–11.5 g/dl) and those who were not
(11.2–11.7 g/dl).
Red blood cell transfusions
In all, 48 patients (15.0 %) received at least one RBC trans-
fusion during the study period. Transfusions were more com-
mon in children aged <1 year and 1–6 years (3/13 [23.1 %]
and 20/83 [24.1 %], respectively) than in the two older age
subgroups (12/90 [13.3 %] and 13/133 [9.8%], respectively).
Transfusions by study period and age group are shown in
Table 6. RBC transfusions were more common in patients
on dialysis at baseline (hemodialysis, 19 [25.7 %]; peritoneal
dialysis, 13 [15.5 %]; no dialysis, 16 [10.0 %]).
The mean pre-transfusion Hb concentration (within the
previous 14 days) was 8.9 g/dl, but individual values varied
widely (median, 8.4 g/dl; range, 5.7–12.7 g/dl; n=37). The
mean pre-transfusion concentration in children aged 6–11
years was lower (8.6 g/dl) than in other children (9.0–9.1 g/
dl). Mean pre-transfusion Hb concentration was also lower in
dialysis patients than non-dialysis patients (8.8 g/dl and 9.2 g/
dl), respectively).
Other endpoints
During the study, 218 (68.3 %) patients were hospitalized on
at least one occasion, with a median length of stay of 16 days
(range, 1–180 days). The proportion of children hospitalized
tended to be higher in those aged <1 year and 1–6 years (84.6
and 74.7 %, respectively) than in the older age subgroups
(60.0 and 68.4 %, respectively). There was little difference
in the hospitalization rate by baseline dialysis status. The
most common reasons for hospitalization were AEs (113
patients; 51.8 % of all those hospitalized), Bnormal clinical
practice^ (75; 34.4 %), and inflammatory conditions (45;
20.6 %).
In all, 229 patients (71.8 %) received supplementary iron
during the study (oral, 107; parenteral, 89); the ratio of oral to
parenteral iron preparations was similar across all age sub-
groups. In those on dialysis at baseline, more patients re-
ceived iron parenterally than orally (n=65 and n=42, respec-
tively), but in those not on dialysis at baseline, the opposite


























































































































































































































































































































































































































































































































































































































Fig. 2 a Weight-adjusted geometric mean dose of darbepoetin alfa per
month by administration route (full analysis set); error bars show 95 %
confidence intervals. i.v., intravenous; s.c., subcutaneous. b Weight-
adjusted geometric mean dose of darbepoetin alfa per month by age
subgroup (full analysis set); error bars show 95 % confidence intervals.
cWeight-adjusted geometric mean dose of darbepoetin alfa per month by
dialysis status at two-monthly intervals (full analysis set). d Mean
hemoglobin concentrations for each age subgroup (full analysis set);
error bars show 95 % confidence intervals
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Discussion
To our knowledge, the current observational study is the first
to assess safety and tolerability of DA treatment for a period of
up to 2 years in anemic children with varying stages of CKD.
At baseline, the sample comprised almost equal numbers of
children on dialysis and not on dialysis, with the former group
containing similar numbers of hemodialysis and peritoneal
dialysis patients. For most patients, the study period did not
represent the first 2 years of DA therapy, as most had already
received DA in the year before study entry. In addition, the
range of DA treatment duration during the study varied, with
approximately one-half of the enrolled patients withdrawing
from the study before the end of the 2-year follow-up.
Approximately 50 % of the children in the study experi-
enced an SAE. This proportion is consistent with a population
with deteriorating renal function—approximately two-thirds
of the patients required hospitalization on at least one occasion
during the study period, and over one-third withdrew after
receiving a kidney transplant. It is notable that similar propor-
tions of children have reported SAEs in studies with much
shorter follow-up periods. For example, in a 28-week compar-
ison of DA and rHuEpo in children aged 1–18 years, 32/81
(40 %) children on DA reported SAEs, most commonly fever,
sepsis, and administration site complications or infections
[12], and another 28-week study reported SAEs in 13
(43 %) of 30 children receiving DA [13]. None of the six fatal
SAEs reported in the current study was judged by the physi-
cian to be causally related to DA treatment.
Six SADRS (i.e., SAEs judged by the treating physician to
be associated with exposure to DA), were reported in four
children. Although thrombosis and embolism are recognized
adverse reactions to DA in adults [10], the SADRs reported in
the other three patients are not. In these three patients, limited
information was collected on underlying conditions and con-
current medications. The patient who reported temporary
blindness suffered from hemolytic uremic syndrome, which
was diagnosed before DA treatment started and was consid-
ered by the investigator as the cause of the temporary blind-
ness. This patient was on hemodialysis and had ‘chronically
elevated blood pressure’ (no blood pressure readings were
recorded). In the case of the patient with hemolysis, hemolytic
anemia, and thrombocytopenia, DA and other unspecified
medications were discontinued, and the events did not recur
after reintroduction of DA. The patient with priapism had a
history of nephrotic syndrome, which is known to be associ-
ated with priapism; however, priapism also occurred in one
patient in the rHuEpo comparison study [12], where it was
classed as a treatment-related AE. Thus, no new safety signals
associated with DA use were identified in this study. The most
frequently reported EMIs were hypertension and convulsions
(affecting 4.7 and 3.1 % of patients, respectively), both recog-
nized as ADRs in adults with chronic renal failure [10]. Fif-
teen of the patients with AEs of hypertension or hypertensive
crisis had this condition at baseline and were receiving treat-
ment for it.
Although the weight-adjusted dose of DA was generally
stable over the 2-year study period, it was slightly but consis-
tently higher in younger than in older children. A possible
explanation is that relatively more children aged <6 years
were on dialysis at baseline and so required higher doses,
which is consistent with the relatively higher requirement for
RBC transfusions by the children in this age subgroup com-
pared with children aged 6 years or more. There did not,
however, appear to be a difference between age subgroups
in the degree of anemia at baseline; the slightly lower mean
Hb in children aged <1 year compared with the other children
was in line with age-related differences in threshold values for
anemia [17].
After rising slightly during the first 3 months following
enrollment, mean Hb concentrations remained stable during
the remainder of the study. This stability in mean Hb values
was seen in all children aged 1 year or older, but in the 13
infants aged <1 year, mean Hb concentrations were noticeably
lower in the first 12 months than in the second 12 months.
This might simply reflect the natural increase in Hb over
2 years that would be expected in a child aged <1 year at
enrollment [18]. Together with the relatively low proportion
of patients requiring RBC transfusion (15 %), these findings
suggest that DA was effective in managing anemia in these
patients. This result is in line with that of a previous study of
DA in 39 children aged 11–18 years in which most patients
achieved stable Hb concentrations after 6 months, whether
they had switched to DA from rHuEpo or were ESA-naive
Table 6 Number of patients receiving red blood cell transfusions by age subgroup in each study period. Some patients were transfusedmore than once
during the study. Values in parentheses are percentages of the number of patients at the start of the respective period
Time period Aged <1 year (n=13) Aged 1–5 years (n=83) Aged 6–11 years (n=90) Aged ≥12 years (n=133)
1–6 months 1 (7.7) 10 (12.0) 7 (7.8) 6 (4.5)
7–12 months 1 (10.0) 6 (9.5) 3 (3.8) 3 (2.9)
13–18 months 1 (14.3) 5 (9.6) 5 (7.8) 5 (6.0)
19–24 months 0 (0) 3 (7.0) 2 (4.2) 1 (1.4)
>24 months 0 (0) 0 (0) 0 (0) 0 (0)
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[19], and with the results of two Japanese studies in children
aged 1–18 years with CKD who switched from rHuEpo or
were ESA-naive [15, 16].
In conclusion, the findings of the current study in a large
and heterogeneous population of children and adolescents
with CKD, in which 145 patients completed 2 years’ follow-
up, add to our understanding of the safety and tolerability
profile of DA in this age group and do not suggest any new
safety signals in comparison with experience with DA in
adults. The stability of DA dose and Hb concentration ob-
served are notable, although the non-interventional design of
the study may limit the extent to which these results can be
generalized to routine clinical practice.
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